MustGrow Biologics (MGRO) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
28 Oct, 2026Market opportunity and positioning
Biologicals market expected to reach ~$20B, with mid-teens CAGR over the next ~5–8 years, within a $380B global market for chemicals, fertilizers and biologicals.
Consumer interest in food production and farmer demand for additional solutions are supporting biologicals’ growth across a broad range of technologies.
TerraMG and TerraSante are positioned as science-backed products; adoption depends on demonstrating field performance and value to growers.
Biologicals are framed as complementary tools in integrated pest management, alongside chemistry, seeds and fertilizers, rather than standalone solutions.
EMEA partnership and market fit
Europe is a priority for biologicals amid stricter regulation, fewer chemical crop-protection options and restrictions on synthetic fertilizers; high-value fruit and vegetable crops are a focus.
Regional consumer demand and regulatory pathways distinguish Europe from North America; local expertise and resources make Bayer a key route into EMEA markets.
Bayer contributes scientific testing, field validation and region-specific regulatory expertise, supporting international development and commercialization.
Bayer sees biologicals as part of farmers’ broader toolkit for crop protection, performance and more responsible food systems; partnerships can help scale solutions to more growers.
TerraMG evaluation and progress
A technical milestone confirmed TerraMG formulation compatibility with European farming practices and standard application equipment, with effective handling and application.
Field studies under real conditions confirmed meaningful disease control, with assessment focused on soil-borne diseases.
Bayer’s nearly two-year pre-partnership evaluation included lab and greenhouse tests, field trials, EU regulatory feasibility and intellectual-property assessment; the commercial agreement followed in Dec 2023.
Bayer highlighted TerraMG’s fit with demand for effective biological alternatives to address nematode-related crop yield and quality losses, particularly in fruits and vegetables.
Latest events from MustGrow Biologics
- TerraSante demand outpaces supply as TerraMG advances through Bayer-backed registration.MGRO
20th International Investment Forum (IIF) - Rapid growth in sustainable agriculture with commercialized biologics and global partnerships.MGRO
Corporate presentation - $1.4M licensing milestone, profit recovery, and 46% sales growth despite margin pressure.MGRO
Q2 2026 - Biological ag products TerraSANTE and TerraMG target rapid growth in a $380B global market.MGRO
Corporate presentation - First TerraSante sales and improved margins highlight Q1-2026 amid production scaling and refocus.MGRO
Q1 2026 - 2025 revenue hit CAD 8.3M as TerraSante sales soared 377%, despite a higher net loss.MGRO
Q4 2025 - Record $3.8M Q1-2025 revenue and 14.3% margin mark pivotal growth post-NexusBioAg acquisition.MGRO
Q1 2025 - Record Q2-2025 revenue and margin growth fueled by surging U.S. TerraSante™ sales.MGRO
Q2 2025 - Gross margin rose to 22.9% in Q3, with strong demand setting up a robust Q4.MGRO
Q3 2025